BD MAX™ Molecular Diagnostic Respiratory
Viral Panel CE Marked to IVD Directive
FRANKLIN
LAKES, N.J., June 30,
2022 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
announced that the BD MAX™ Respiratory Viral Panel (RVP), a new
molecular diagnostic combination test for SARS-CoV-2, Influenza A +
B and Respiratory Syncytial Virus (RSV), has been CE marked to the
IVD directive 98/79/EC.
The test uses a single nasal swab or a single nasopharyngeal
swab sample to determine if a patient has COVID-19 or the flu or
RSV. It helps eliminate the need for multiple tests or doctor
visits and can help clinicians to implement the right treatment
plan quickly. The co-testing approach also helps to
increase testing capacity during the busy flu season and speeds the
time to diagnosis.
"SARS-Cov-2, influenza and RSV are a triple threat, as patient
symptoms and clinical presentation can be nearly identical," said
Nikos Pavlidis, vice president of
Molecular Diagnostics at BD. "A combined testing panel is key to
enabling clinicians to quickly and efficiently diagnose,
differentiate and treat patients to help manage the spread of the
infections."
The BD MAX™ System, a molecular diagnostic platform, is already
in use at thousands of laboratories worldwide, and each unit is
capable of analyzing hundreds of samples over a 24-hour period. The
BD MAX™ RVP assay is an RT- PCR assay that detects and
differentiates the mRNA of SARS-CoV-2, flu A, flu B and RSV in
approximately two hours, with the easy-to-use and automated
workflow of the BD MAX™ System.
The BD RVP assay for BD MAX™ System is an important addition to
the extensive number of assays available on the system across
respiratory, STI, gastrointestinal, women's health and health care
associated infections. The broad menu of assays in combination with
the open system capabilities on a fully automated sample-to-result
molecular platform make the BD MAX™ System a valued platform for
infectious disease testing in thousands of labs worldwide.
BD MAX™ RVP is currently available in countries that recognize
the CE mark. BD plans to submit for Emergency Use Authorization
from the U.S. Food and Drug Administration in the coming weeks.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 75,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts:
|
|
|
|
Media:
|
Investors:
|
Troy Kirkpatrick
|
Francesca
DeMartino
|
VP, Public
Relations
|
SVP, Head of Investor
Relations
|
858.617.2361
|
201.847.5743
|
troy.kirkpatrick@bd.com
|
francesca.demartino@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-launches-combination-test-for-covid-19-influenza-ab-and-respiratory-syncytial-virus-301578512.html
SOURCE BD (Becton, Dickinson and Company)